Narrative synthesis of published literature
Trazodone Augmentation Studies for Depression
What the research literature generally describes about adding low-dose trazodone to another antidepressant, primarily for sleep-related benefit.
Published August 8, 2026. Reviewed by our editorial team on August 8, 2026.
Who was studied: Patients with depression and sleep disturbance on another primary antidepressant, across published clinical literature
Trazodone augmentation — adding a low dose to an existing antidepressant, usually at bedtime — is a well-established clinical practice, and the published literature examining it generally focuses on two overlapping questions: does it help sleep, and does it add any independent antidepressant benefit beyond that?
The sleep-benefit finding is fairly consistent across the available literature. The independent antidepressant-augmentation benefit is less consistently demonstrated — some of the apparent mood improvement in augmentation studies may be explained by improved sleep itself, which is well known to affect mood and daytime functioning. This nuance matters for setting realistic expectations if trazodone is added specifically for sleep versus specifically hoping for an additional mood effect.
Main result: Published literature on trazodone augmentation generally describes benefit for sleep-related symptoms when added to a primary antidepressant such as an SSRI, with less consistent evidence for a distinct additional antidepressant effect beyond the sleep benefit itself.
Limitations: Augmentation studies vary in design, duration, and how they define "benefit," making it difficult to draw a single clean conclusion about how much of trazodone's augmentation benefit is a genuine mood effect versus a downstream effect of improved sleep.
Not medical advice. This summary is educational and does not replace individualized guidance from your prescriber.
